[1]舒静波,刁勇,肖卫东,等.腺病毒-腺相关病毒嵌合载体的研发趋势[J].华侨大学学报(自然科学版),2008,29(2):172-176.[doi:10.11830/ISSN.1000-5013.2008.02.0172]
　SHU Jing-bo,DIAO Yong,XIAO Wei-dong,et al.The Development Trend of Chimeric Vector of Adenovirus/Adeno Associated Viral[J].Journal of Huaqiao University(Natural Science),2008,29(2):172-176.[doi:10.11830/ISSN.1000-5013.2008.02.0172]
点击复制

腺病毒-腺相关病毒嵌合载体的研发趋势()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第29卷
期数:
2008年第2期
页码:
172-176
栏目:
出版日期:
2008-04-20

文章信息/Info

Title:
The Development Trend of Chimeric Vector of Adenovirus/Adeno Associated Viral
文章编号:
1000-5013(2008)02-0172-05
作者:
舒静波; 刁勇; 肖卫东; 曾棠埭; 许瑞安
华侨大学材料科学与工程学院; 滨州大学医学院; 泉州医学高等专科学校; 华侨大学材料科学与工程学院 福建泉州362021; 福建泉州362021; 美国宾夕法尼亚州; 福建泉州362011
Author(s):
SHU Jing-bo1;  DIAO Yong1;  XIAO Wei-dong2;  ZENG Tang-dai3;  XU Rui-an1
1.Institute of Molecular Pharmacology, Huaqiao University, Quanzhou 362021, China; 2.School of Medicine, Pennsylvania State University, Pennsylvania, America; 3.Quanzhou Medical College, Quanzhou 362000, China
关键词:
载体系统;  腺病毒;  腺相关病毒;  嵌合;  临床治疗
Keywords:
vector system;  adenovirus;  adeno-associated virus;  hybrid vectors;  clinical therapy
分类号:
Q78
DOI:
10.11830/ISSN.1000-5013.2008.02.0172
文献标志码:
A
摘要:
分析腺病毒-腺相关病毒(Ad/AAV)嵌合载体母体中,3代Ad载体及AAV载体所具有的优势和存在的缺点.阐述Ad/AAV嵌合载体的制备方法、生产工艺,以及其在稳定转染造血干细胞、Duchenne型肌营养不良症(DMD)的基因治疗和人内啡肽基因的表达研究等方面的最新研究进展.同时指出,Ad/AAV嵌合载体是近年发展起来的嵌合病毒载体,它融合了Ad和AAV两种常用的病毒载体的优点,理论上接近理想临床应用的载体,但还需要通过大量的,特别是动物体内的应用研究去检验其优越性,以满足临床治疗需要.
Abstract:
Analyze three generations of the Ad and AAV′s exhibits advantages and disadvantages in the capsid of adenovirus/adeno-associated virus Hybrid vectors.This article focuses on the latest development of design technique,produce technics,stable transduce Human Hematopoietic cells,duchenne muscular dystrophy ′s gene therapy,and Express analysis the fusion gene of human β-endorphin and so on,for adenovirus/adeno-associated virus Hybrid vectors,besides adenovirus/adeno-associated virus Hybrid vectors is developed just in latest years,it takes advantage of Ad and AAV vector,achieve clinical application′s perfect purpose in theory,but it requires large numbers of experiments to test its advantage,especially experiment with animal,to fulfil the clinical therapy.

参考文献/References:

[1] CAVAZZANA-CALVO M, HACEIN-BEY S, DE SAINT BASILE G. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J]. Science, 2000.669-672.
[2] HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy [J]. New England Journal of Medicine, 2002.1185-1193.doi:10.1056/NEJMoa012616.
[3] KAY M A, MANNO C S, RAGNI M V. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector [J]. Nature Genetics, 2000.257-261.
[4] AIUTI A, SLAVIN S, AKER M. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning [J]. Science, 2002.2410-2413.
[5] CHECK E. Gene therapy put on hold as third child develops cancer [J]. NATURE, 2005.561.
[6] FRAEFEl C, BREAKEFIELD X O. Hybrid vectors:A new generation of virus-based vectors designed to control the cellular fate of delivered genes [J]. Gen Therapy, 1997(4):1281-1283.
[7] FISHER K J. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome [J]. Human Gene Therapy, 1996(7):2079-2087.
[8] 刁勇, 王广基, 许瑞安. 基因治疗研究进展 [J]. 药学进展, 2001(1):12-16.doi:10.3969/j.issn.1001-5094.2001.01.004.
[9] LEHRMAN S. Virus treatment questioned after gene therapy death [J]. Nature, 1999.517-518.
[10] RECCHIA A, PARKS R J, LAMARTINA S. Site-specific integration mediated by a hybrid adenovirus/adenoassociated virus vector [J]. Proceedings of the National Academy of Sciences(USA), 1999.2615-2620.
[11] LIEBER A, STEINWAERDER D S, CARLSON C A. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes [J]. Virology, 1999.9314-9324.
[12] GONCALVES M A, VELDE I, JANSSEN J M. Efficient generation and amplification of high-capacity adeno-associated virus/adenovirus hybrid vectors [J]. Virology, 2002.10734-10744.
[13] GONCALVES MAFV, NIEROP G P, TIJSSEN M R. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability [J]. Virology, 2005(5):3146-3162.
[14] SHAYAKHMETOV D M, CARISON C A, STECHER H. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells [J]. Virology, 2002.1135-1143.doi:10.1128/JVI.76.3.1135-1143.2002.
[15] 徐学武, 俞卫锋, 崔贞福. 表达人内啡肽的腺病毒P腺相关杂合病毒的构建及体外表达分析 [J]. 微生物学报, 2005(6):856-859.doi:10.3321/j.issn:0001-6209.2005.06.008.
[16] 许瑞安, 刁勇, 谢海棠. 基因药物在临床上的最新应用和研发 [J]. 中国临床药理学与治疗学杂志, 2006, (10):1092-1097.doi:10.3969/j.issn.1009-2501.2006.10.003.
[17] 曲光, 徐韬, 王晋慧. 基因药物的构建与制备 [A]. 北京:北京大学出版社; 北京:北京大学医学出版社, 2007.1-35.

更新日期/Last Update: 2014-03-23